Suchergebnisse - "d'Ettorre, Gabriella"

PubPharm (18)

1

Retinal involvement and ocular findings in COVID-19 pneumonia patients

enthalten in: Scientific reports | 2020

von Pirraglia, M. | Ceccarelli, G. | Cerini, A. | +6

2

Sex-related differences in markers of immune activation in virologically suppressed HIV-infected patients

enthalten in: Biology of sex differences | 2020

von Santinelli, L. | Ceccarelli, G. | Borrazzo, C. | +7

3

Copy-Years Viremia and Risk of Virological Failure in Long-Term-Treated HIV Patients

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2019

von Falasca, F. | De Vito, C. | Mazzuti, L. | +7

4

Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities : is it time to assess the definitions?

enthalten in: AIDS (London, England) | 2019

von Trunfio, M. | Pinnetti, C. | Focà, E. | +10

5

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients : 96 week outcomes of a randomized trial

enthalten in: The Journal of antimicrobial chemotherapy | 2018

von Fabbiani, M. | Gagliardini, R. | Ciccarelli, N. | +120

6

Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals

enthalten in: Nutrients | 2017

von Ceccarelli, G. | Brenchley, J. | Cavallari, E. | +9

7

Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial

enthalten in: The Journal of antimicrobial chemotherapy | 2017

von Lombardi, F. | Belmonti, S. | Quiros-Roldan, E. | +9

8

Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients : 48 week results from a randomized trial (ATLAS-M)

enthalten in: The Journal of antimicrobial chemotherapy | 2017

von Di Giambenedetto, S. | Fabbiani, M. | Quiros Roldan, E. | +19

9

Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens

enthalten in: AIDS research and human retroviruses | 2015

von Baroncelli, S. | Pirillo, M. | Galluzzo, C. | +12

10

Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control : 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)

enthalten in: Scandinavian journal of infectious diseases | 2014

von Fabbiani, M. | Mondi, A. | Colafigli, M. | +11